Current Liabilities
Accounts Payable
Neurocrine Biosciences Accounts Payable increased by 14.6% to $773.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 62.7%, from $475.20M to $773.00M. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 31.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase can signal improved cash management or extended payment terms, while a decrease may indicate faster payments to suppliers or reduced purchasing activity.
Detailed definition
This represents the short-term obligations owed to suppliers and vendors for goods and services received on credit. It i...
Peer comparison
Standard current liability for all companies; comparable across industries based on days payable outstanding.
Metric ID:
accounts_payableHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $190.90M | $205.90M | $225.80M | $235.90M | $265.70M | $297.80M | $347.60M | $355.70M | $391.60M | $503.00M | $448.80M | $417.20M | $358.50M | $392.70M | $461.60M | $475.20M | $489.50M | $584.30M | $674.30M | $773.00M |
| QoQ Change | — | +7.9% | +9.7% | +4.5% | +12.6% | +12.1% | +16.7% | +2.3% | +10.1% | +28.4% | -10.8% | -7.0% | -14.1% | +9.5% | +17.5% | +2.9% | +3.0% | +19.4% | +15.4% | +14.6% |
| YoY Change | — | — | — | — | +39.2% | +44.6% | +53.9% | +50.8% | +47.4% | +68.9% | +29.1% | +17.3% | -8.5% | -21.9% | +2.9% | +13.9% | +36.5% | +48.8% | +46.1% | +62.7% |
Range$190.90M – $773.00M
CAGR+34.2%
Avg YoY Growth+33.2%
Median YoY Growth+41.9%
Current Streak7 quarters growth
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's accounts payable?
- Neurocrine Biosciences (NBIX) reported accounts payable of $773.00M in Q1 2026.
- How has Neurocrine Biosciences's accounts payable changed year-over-year?
- Neurocrine Biosciences's accounts payable increased by 62.7% year-over-year, from $475.20M to $773.00M.
- What is the long-term trend for Neurocrine Biosciences's accounts payable?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's accounts payable has grown at a 31.9% compound annual growth rate (CAGR), from $168.70M to $674.30M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services.